Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: GlobeNewswire
LOS ANGELES, April 17, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB) investors who purchased securities between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”). If you suffered a loss on your AnaptysBio investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information here or contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, via email shareholders@glancylaw.com or visit our website at www.glancylaw.com to learn more about your rights. On March 26, 2018, AnaptysBio revealed data from an interim analysis of a Phase 2a trial for etokimab in adult patients with peanut allergies. Though the Company reported improvement amo
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an "overweight" rating on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Truist Financial Co. from $30.00 to $20.00. They now have a "hold" rating on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Wells Fargo & Company from $56.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- AnaptysBio Stock Down as Eczema Study Fails to Meet Goals [Yahoo! Finance]Yahoo! Finance
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Guggenheim from $90.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
ANAB
Earnings
- 11/5/24 - Beat
ANAB
Sec Filings
- 12/18/24 - Form SCHEDULE
- 12/11/24 - Form 8-K
- 12/3/24 - Form 4
- ANAB's page on the SEC website